What is Elminda?
Elminda, operating under the name Firefly Neuroscience, specializes in advanced brain health analytics. The company leverages its FDA-cleared technology, Brain Network Analytics (BNA), which employs AI-driven assessments to deliver objective measurements of brain activity. This technology assists healthcare professionals in the diagnosis and management of cognitive disorders. Firefly's proprietary database and advanced AI position it as a leader in neurophysiological assessment and biomarker development, aiming to improve patient outcomes and operational efficiency in neurological care.
How much funding has Elminda raised?
Elminda has raised a total of $28M across 1 funding round:
Series C
$28M
Series C (2015): $28M with participation from OurCrowd, WR Hambrecht, Shanda Group, Healthcrest AG, Palisade Capital Management, and Wexford Capital
Key Investors in Elminda
OurCrowd
OurCrowd is an investment platform focused on startups and venture funds, based in Israel.
Shanda Group
Shanda Group is a company operating in the Software industry, headquartered in Beijing, China.
Healthcrest AG
Healthcrest AG provides funding and strategic advice in the healthcare sector, leveraging deep industry knowledge and a network of contacts.
What's next for Elminda?
The substantial enterprise-level funding Elminda has garnered, particularly the recent strategic investment, signals a phase of significant scaling and market expansion. This capital infusion is expected to accelerate the development and deployment of its AI-powered brain health analytics, potentially leading to broader adoption by healthcare providers and further advancements in neurological diagnostics. The company's focus on objective brain activity measurements and biomarker development positions it for continued growth and innovation in the competitive neurotechnology landscape.
See full Elminda company page
